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REVIEW
Tissue-Engineered Blood Vessels in Pediatric
Cardiac Surgery
Toshiharu Shinoka, MD,* Christopher Breuer, MD
Department of Surgery, Yale University School of Medicine, New Haven, Connecticut
Pediatric cardiovascular surgeons often encounter patients requiring surgical intervention
utilizing foreign materials to repair complex lesions. However, the materials that are com-
monly used lack growth potential, and long-term results have revealed several material-re-
lated failures, such as stenosis, thromboembolization, calcium deposition, and risk of
infection. To solve these problems, in particular for children who require the implantation of
dynamic material with growth potential, we sought to develop optimal filling materials with
biocompatibility and growth potential. Previously, we reported the advantages of tissue-en-
gineered vascular autografts (TEVAs†) in animal models and in human clinical applications
utilizing autologous cells and biodegradable scaffolds. The key benefits from utilizing such
scaffolds is that they degrade in vivo, thereby avoiding the long-term presence of foreign ma-
terials, and the seeded cells proliferate and differentiate to construct new tissue.
Recent studies have demonstrated the existence of bone marrow-derived endothelial pro-
genitor cells that contribute to vasculogenesis and angiogenesis and the successful en-
dothelialization of artificial grafts using bone marrow cells. We provided evidence that bone
marrow cells as a source for seeding onto a biodegradable scaffold are useful and that
seeded cells contribute to the histogenesis of TEVAs. Therefore, we applied this technique
in clinical trials with good results. In this review article, we provide an overview of our work
developing “tissue-engineered blood vessels” created by utilizing autologous mononuclear
bone marrow cells.
CONGENITAL HEART DISEASE: A
SIGNIFICANT MEDICAL PROBLEM
Cardiac defects are the most common
congenital anomalies. Despite major ad-
vances in the treatment of congenital heart
disease (CHD), it remains the leading cause
of death due to congenital anomalies in the
newborn period (www.americanheart.org).
Single ventricle anomalies make up one of
the largest groups of cardiac anomalies that
resultinseveredisease.Thoughsuchanom-
aliesdifferstructurally,theyshareacommon
featureinthatonlyoneofthetwoventricles
is of adequate functional size. Some of the
cardiacanomaliesthatresultinsingleventri-
cle changes include tricuspid atresia, pul-
monary atresia, and hypoplastic left heart
syndrome. This group of congenital cardio-
vascular anomalies results in mixing of de-
oxygenated blood from the pulmonary
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tional Review Board.circulation and oxygenated blood from the
systemic circulation. The circulation of de-
oxygenated blood through the systemic cir-
culation causes chronic hypoxia and
cyanosis. Mixing of blood between the pul-
monary and systemic circulation also can
cause volume overload, which, if left un-
treated, can lead to heart failure. Untreated
singleventriclecardiacanomaliesareassoci-
atedwith70percentmortalityduringthefirst
yearoflife[1].Thetreatmentofchoiceissur-
gical reconstruction [2,3]. Without surgery,
survival of this cohort into adulthood is rare.
SURGICAL TREATMENT OF CHD:
LIMITATIONS ASSOCIATED WITH
CURRENTLY USED VASCULAR
CONDUITS
Despite the dramatic structural differ-
ences in the cardiac defects causing single
ventricle physiology, the ultimate plans for
staged surgical reconstruction are actually
quite similar.The goal of these operations is
to separate the pulmonary circulation from
the systemic circulation.This eliminates the
mixing of systemic and pulmonary blood
flow, resulting in improved systemic oxy-
genation and preventing volume overload,
thus normalizing the volume work of the
systemic ventricle, thereby preventing heart
failure. This is accomplished through a se-
ries of staged operations designed to recon-
struct the cardiovascular structures so that
the single ventricle pumps oxygenated blood
through the systemic circulation.The deoxy-
genated blood is then passively circulated
through the pulmonary circulation, where it
is oxygenated and returned to the heart.This
type of surgical procedure is referred to as a
Fontan operation. The Fontan operation has
undergone several modifications since it was
first reported in 1971 [4]. The most com-
monly performed modification of the Fontan
operation is the extra cardiac total cavopul-
monary connection (EC TCPC) (Figure 1).
The modified Fontan operation is consid-
ered the standard of care for the treatment of
patients with single ventricle cardiac anom-
alies and substantially has improved both the
quality and long-term survival of these pa-
tients; however, it is still considered a pal-
liative (non-curative) procedure with
significant morbidity and mortality [2,3].
One important cause of morbidity and mor-
tality in patients requiring the Fontan oper-
ation is the conduit used to connect the
inferior vena cava to the right pulmonary ar-
tery when native tissue cannot be used [5].
When Fontan and Kirklin reviewed the late
outcome of an early cohort of patients sur-
viving the Fontan procedure, they concluded
that much of the late morbidity could be at-
tributed to problems associated with conduit
use [6]. It is widely accepted that the ideal
conduit has not yet been developed [7,8].
Polytetrafluoroethylene (PTFE, or Gore-
Tex®) conduits are currently the most
widely used vascular grafts for EC TCPC
[9]. Use of PTFE essentially has replaced
the use of Dacron in most centers. Failure
rates for Dacron grafts used for ECTCPC is
limited but tends to be worse than PTFE fail-
ure rates described in the literature [2]. Ho-
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Figure 1: Schematic Diagram of EC TCPC.
In this modified Fontan operation, venous re-
turn from the lower half of the body is pas-
sively returned to the pulmonary artery by
anastomosing the IVC to the pulmonary ar-
tery using a conduit. Blood is then oxy-
genated in the pulmonary circulation and
returned to the single ventricle, where it is
pumped through the systemic circulation.mografts also are used as EC TCPC con-
duits, but to a much more limited extent
compared to PTFE [3].
While data describing the long-term
graft failure rates for conduits used for EC
TCPC is limited, long-term data regarding
use of both valved and unvalved conduits
for other similar congenital heart operations
such as the Rastelli operation (right ventricle
to pulmonary artery conduit) are widely
available and are poor [10]. Late problems
include conduit degeneration with progres-
sive obstruction, lack of growth potential,
potential for infection, and potential for
thromboembolic complications. Both syn-
thetic and biological conduits are used for
these operations. PTFE and other synthetic
conduits such as Dacron lack growth poten-
tial necessitating re-operation when a patient
outgrows his vascular graft. Synthetic con-
duits are a significant cause of thromboem-
bolic complication due to the large area of
synthetic material in contact with blood that
causes activation of the coagulation cascade
[3]. Other clinically available conduits, in-
cluding biological grafts such as homografts
and heterografts, are associated with signif-
icantly lower thromboembolic complication
rates compared to synthetic grafts; however,
they, too, lack growth potential and unfortu-
nately have poor durability due to their
propensity for accelerated calcific degrada-
tion and secondary graft failure [11,12,13].
These grafts tend to become stenotic and
calcify. This process seems to be immune
mediated and more aggressive in younger
patients [14]. It is basically assumed that all
such conduits eventually will need to be re-
placed [15]. Re-operations are associated
with significant morbidity and mortality
with early post-operative mortality rates
around 5 percent in the best centers [10].
Early and mid-term results for these grafts
are variable with five-year patency rates be-
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Table: Results of IRB-approved Japanese clinical study (adapted Shinoka, 2005)
Patients
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
BW
11
7.5
18.5
44.4
14
36.7
46.5
47
13.5
7.5
11
23
9.9
9.32
11
8.67
51.6
8.7
25.5
11
10.5
13
14.2
Age
2
1
7
21
4
12
17
19
3
2
2
13
2
2
2
2
24
1
11
2
3
4
4
Diameter of
Scaffolds
(mm)
16
20
18
24
20
24
24
22
12
16
16
20
16
18
12
16
18
16
18
12
16
18
18
Component of
Biodegradable
Scaffold
PCLA/PLA
PCLA/PLA
PCLA/PLA
PCLA/PLA
PCLA/PLA
PCLA/PLA
PCLA/PLA
PCLA/PLA
PCLA/PLA
PCLA/PLA
PCLA/PGA
PCLA/PLA
PCLA/PGA
PCLA/PGA
PCLA/PGA
PCLA/PGA
PCLA/PGA
PCLA/PGA
PCLA/PGA
PCLA/PGA
PCLA/PGA
PCLA/PGA
PCLA/PGA
Day of
Surgery
2001.9.17
2001.10.29
2002.1.25
2002.3.27
2002.6.3
2002.6.13
2002.7.1
2002.9.25
2002.10.17
2002.12.6
2003.3.17
2002.4.10
2003.5.21
2003.6.16
2003.6.27
2003.8.25
2003.9.25
2003.10.1
2003.10.27
2003.11.10
2004.1.27
2004.2.1
2004.3.12
Duration
of
Follow-up
(years)
5.77
5.66
5.42
5.24
5.06
5.03
4.98
3.57
4.69
0.47
4.27
5.21
4.09
4.03
3.99
3.83
3.75
3.73
3.66
3.63
3.41
3.40
3.29
Graft/Related
Complication
None
None
None
None
None
None
None
None
None
None
stenosis
None
None
None
None
None
None
None
None
None
None
None
None
Current
status
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Late
death
(heart
failure)
Alive
Late
death
(heart
failure)
Alive,
PTA*
(2005.7.
15)
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
*PTA: percutaneous transluminal balloon angioplastytween 65 and 90 percent. Long-term data
demonstrating graft failure rates between 70
and 100 percent at 10 to 15 years have been
reported [11,13,16]. Primary determinants of
graft failure include size (with an increased
rate of failure in grafts less than 18 mm with
another significant drop off below 15 mm)
and re-operation (with primary grafts per-
forming better than replacement grafts) [16].
The best long-term results have been ob-
tained when autologous tissue has been used
for or incorporated into the conduit with
long-term patency rates exceeding 80 per-
cent [15].
DEVELOPMENT OF THE
AUTOLOGOUS TISSUE-
ENGINEERED VASCULAR GRAFT
Autografts, conduits created from autol-
ogous tissue, have better long-term effec-
tiveness than any synthetic or biological
conduit currently available for use in pedi-
atric cardiovascular surgical applications
[10,15,17]. Unfortunately, autografts are
limited in supply, necessitating the use of
synthetic or biological conduits in most
cases [16]. Use of synthetic or biological
vascular grafts result in increased graft fail-
ure rates and increased morbidity and mor-
tality rates when compared to similar
operations performed using autologous tis-
sue [13,15]. Tissue engineering offers a
strategy for constructing autologous grafts
and thereby increasing the pool of potential
autografts. Using the classical tissue engi-
neering paradigm, autologous cells can be
seeded onto a biodegradable tubular scaf-
fold. The scaffold provides sites for cell at-
tachment and space for neotissue formation
[18].The resulting neotissue can be used for
reconstructive surgical applications such as
creation of a vascular graft for use in pedi-
atric cardiothoracic operations [17]. Exten-
sive large animal studies have demonstrated
the feasibility of using tissue engineering
methodology to construct a conduit for use
as large caliber grafts in the venous or pul-
monary circulation [17,19,20,21,22].
In the mid 1990s, we performed a series
of experiments applying the classical tissue
engineering paradigm toward the develop-
ment of a neotissue for use in reconstructive
cardiovascular surgical applications. During
this time, we demonstrated the feasibility of
creating a tissue-engineered vascular graft
for use in congenital heart surgery [17].
The initial scaffold was constructed
from off-the-shelf biodegradable polymers
originally designed for other biomedical ap-
plications. While creating a tissue-engi-
neered vascular graft with this scaffold was
feasible, the design of the PGAscaffold was
not optimal due to the relatively stiff nature
of the PGAfibers that resulted in poor com-
pliance match and poor surgical handling
qualities.The hybrid polymeric scaffold fab-
ricated from either polyglycolic or polylactic
acid fiber-based mesh coated with a 50:50
copolymer of L-lactide and ε-caprolactone
(PCLA/PGA or PCLA/PLA) was specifi-
cally designed for use as a biodegradable
scaffold for creating a tissue engineered vas-
cular graft. The hybrid scaffolds are more
elastic than the PGAscaffold, resulting in an
improved compliance match between the
vessel and the conduit and with better surgi-
cal handling characteristics [19].
In our initial studies, vascular cells were
isolated from autologous vessel biopsies.
This methodology was problematic for
many reasons. First, it required an invasive
procedure (biopsy) in addition to the need
for a substantial period of time in order to
expand the cells in culture that limited its
clinical utility. As our experience grew, we
also began to recognize the inherent diffi-
culty in obtaining healthy autologous cells
from diseased donors. Finally, use of cell
culture resulted in an increased risk of con-
tamination of the cultured cells. In an at-
tempt to identify an alternative autologous
cell source that could be obtained with min-
imal manipulation and without the use of
cell culture, we explored the use of autolo-
gous cells obtained from bone marrow aspi-
rate [21].
We further refined our method in order
to remove platelets and red blood cells and
eliminate the inherent thrombogenic risk as-
sociated with use of these cell types by per-
forming density centrifugation and isolating
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row.This technique had the added benefit of
providing a source of autologous serum that
could be used instead of media to bathe the
seeded scaffold during the brief period of
time the cells were in contact with the scaf-
fold ex vivo [22].
TISSUE-ENGINEERED VASCULAR
AUTOGRAFT (TEVA) CLINICAL TRIAL
We reported the first clinical use of a
TEVAforuseasanextracardiactotalcavopul-
monary connection (EC TCPC) conduit
[23,24,25]. This study was performed under
anInstitutionalReviewBoard(IRB)approved
protocol at Tokyo Women’s Hospital, Tokyo,
Japan. To date, 23 tissue-engineered vascular
graftshavebeenimplantedasconduitsforEC
TCPC with follow-up through six years
[21,24](Table).Thetissue-engineeredvascu-
largraftsfunctionedwellwithoutevidenceof
aneurismal change or graft rupture. There
have been three graft-related complications:
the development of significant stenosis in a
smaller diameter (< 18 mm) conduit that re-
quired and was successfully treated with an-
gioplasty. There were no reported
thromboembolic or hemorrhagic complica-
tionsorinfectiouscomplications.Nografthas
hadtobereplaced.Serialimaginghasdemon-
strated the growth potential of these grafts.
These data support the overall feasibility and
safety of this technology (Figure 2). We have
received IRB approval and have applied for
FDAapproval for the first clinical trial inves-
tigatingtheuseofTEVAintheUnitedStates.
CONCLUSION
Successful translation of cardiovascular
tissue engineering principles from the bench
to the clinic through the development of an
improved venous conduit for repair of con-
genital heart defects also could be utilized to
create improved vascular grafts for a variety
ofothercardiovascular surgicalapplications.
Theneedforimprovedvasculargraftsforan-
gioaccessforpatientsrequiringhemodialysis
for treatment of end stage renal disease af-
fects more than 375,000 patients in the
United States alone. Currently used vascular
grafts require endovascular interventions or
replacement within two years of implanta-
tion. Similarly, clinical results associated
with use of synthetic small caliber vascular
grafts for the treatment of both cardiovascu-
lar and peripheral arterial disease are so poor
as to prohibit their use in most circum-
stances.Itisestimatedthatcreationofanim-
proved small caliber arterial graft would
affectthelivesofmorethan100,000patients
per year in the United States. These patients
require life- or limb-saving operations that
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Figure 2
A. Magnetic resonance image 9 months after
implantation of TCPC graft. White arrow indi-
cates location of tissue-engineered conduit.
B. 3-D CT angiogram of tissue-engineered
EC TCPC one year after implantation.suffer from the same limitations due to inad-
equatevasculargraftsascongenitalheartop-
erations. Using the same basic tissue
engineering methodologies described in this
proposal, we could continue to expand upon
our current work and begin to address these
critical health issues.
Tissue engineering holds great promise
for the advancement of all fields of medi-
cine. The ability to create tissue from an in-
dividual’s own cells that can be used to
replace tissues that are diseased, destroyed,
or congenitally absent without the risk of re-
jections and improved biocompatibility dra-
matically could improve our ability to treat
a variety of the most serious medical prob-
lems affecting our society.
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